Novo Nordisk Secures US Approval for WEGOVY
Novo Nordisk has achieved a significant regulatory milestone with the U.S. FDA approval of WEGOVY (semaglutide) for the treatment of obesity in pediatric patients aged 12 years and older. While WEGOVY has already revolutionized the adult weight management market, this expansion into the adolescent population addresses a critical public health crisis. The approval is specifically for pediatric patients with an initial Body Mass Index (BMI) at or above the 95th percentile for their age and sex. The medication is intended as an add-on to a reduced-calorie diet and increased physical activity, mirroring the protocol establish...